Study shows promise of precision medicine for most common type of lymphoma
Monday, July 20, 2015 - 12:30
in Health & Medicine
Patients with a specific molecular subtype of diffuse large B-cell lymphoma are more likely to respond to the drug ibrutinib (Imbruvica) than patients with another molecular subtype of the disease, a new study shows.